Press Releases

Press Releases

Date	Title	View
November 9, 2023	AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 6, 2023	AN2 Therapeutics to Present at Upcoming Investor Conferences
October 18, 2023	AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
October 11, 2023	AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
September 26, 2023	AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 13, 2023	AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
August 15, 2023	AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
August 10, 2023	AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
May 25, 2023	AN2 Therapeutics to Present at Jefferies Healthcare Conference
May 11, 2023	AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

Investors